Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

Annals of Oncology

Volumn 21, Issue 1, 2009, Pages 98-103

  Larbouret, C ^a,b,c,d   Robert, B ^a,b,c,d   Bascoul Mollevi, C ^d   Penault Llorca, F ^e   Ho Pun Cheung, A ^d   Morisseau, S ^a,b,c,d   Navarro Teulon, I ^a,b,c,d   Mach, J P ^f   Pelegrin A ^a,b,c,d   Azria, D ^a,b,c,d  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d CENTRE VAL D AURELLE   (France)

^e CENTRE JEAN PERRIN   (France)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

EGFR; Gemcitabine; HER2; Monoclonal antibodies; Pancreatic carcinoma

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; K RAS PROTEIN; PROTEIN KINASE B; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GROWTH INHIBITION; MOUSE; MUTATION; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR REGRESSION;

EID: 77949314352     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp496     Document Type: Article

References (23)

1. Nelson NJ. Pancreatic cancer research matures. J Natl Cancer Inst 2007; 99: 1432-1434.
2. Heinemann V, Boeck S, Hinke A et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
3. Herman JM, Swartz MJ, Hsu CC et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26: 3503-3510.
4. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3487-3495.
5. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
6. Tobita K, Kijima H, Dowaki S et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003; 11: 305-309.
7. Dugan MC, Dergham ST, Kucway R et al. HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival. Pancreas 1997; 14: 229-236.
8. Ye D, Mendelsohn J, Fan Z. Augmentation of an anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999; 18: 731-738.
9. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
10. Friedman LM, Rinon A, Schechter B et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci U S A 2005; 102: 1915-1920.
11. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
12. Larbouret C, Robert B, Navarro-Teulon I et al. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 2007; 13: 3356-3362.
13. Ben-Kasus T, Schechter B, Lavi S. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 2009; 106(9): 3294-3299.
14. Germain C, Larbouret C, Cesson V et al. MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res 2005; 11: 7516-7522.
15. Mimura K, Kono K, Hanawa M et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 4898-4904.
16. Cogoi S, Codognotto A, Rapozzi V et al. Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide. Biochemistry 2005; 44: 10510-10519.
17. Butz J, Wickstrom E, Edwards J. Characterization of mutations and loss of heterozygosity of p53 and K-ras2 in pancreatic cancer cell lines by immobilized polymerase chain reaction. BMC Biotechnol 2003; 3: 11.
18. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
19. Cascinu S, Berardi R, Labianca R et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9: 39-44.
20. Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 6390-6399.
21. Clynes RA, Towers TL, Presta LG et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-446.
22. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7: 715-725.
23. Delaloye B, Bischof-Delaloye A, Buchegger F et al. Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab′)2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 1996; 77: 301-311.